The Future of Biologic Agents in the Treatment of Sjoegren's Syndrome

The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjoegren's syndrome (SS) and the current availability of various biological agents (anti-TNF- alpha , IFN- alpha , anti-CD20, and anti-CD22) have resulted in new strategies for therapeu...

Full description

Saved in:
Bibliographic Details
Published in:Clinical reviews in allergy & immunology 2007-06, Vol.32 (3), p.292-297
Main Authors: Meijer, J M, Pijpe, J, Bootsma, H, Vissink, A, Kallenberg, CGM
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The gain in knowledge regarding the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of Sjoegren's syndrome (SS) and the current availability of various biological agents (anti-TNF- alpha , IFN- alpha , anti-CD20, and anti-CD22) have resulted in new strategies for therapeutic intervention. In SS, various phase I and II studies have been performed to evaluate these new strategies. Currently, B cell-directed therapies seem to be more promising than T cell-related therapies. However, large, randomized, placebo-controlled clinical trials are needed to confirm the promising results of these early studies. When performing these trials, special attention has to be paid to prevent the occasional occurrence of the severe side effects.
ISSN:1080-0549
DOI:10.1007/s12016-007-8005-6